Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

References

• [ARC Recommendations] Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 updateAmerican College of Rheumatology Subcommittee on Osteoarthritis GuidelinesArthritis Rheum20004319051511014340
   PubMed Web of Science ®Google Scholar
• AntmanEMBennettJSDaughertyAAmerican Heart AssociationUse of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart AssociationCirculation200711516344217325246
   PubMed Web of Science ®Google Scholar
• ArmstrongCPBlowerALNon-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerationGut198728527323596334
   PubMed Web of Science ®Google Scholar
• BannwarthBBerenbaumFClinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitorExpert Opin Investig Drugs20051452133
   PubMed Web of Science ®Google Scholar
• BombardierCLaineLReicinAVIGOR Study GroupComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med20003431520811087881
   PubMed Web of Science ®Google Scholar
• BresalierRSSandlerRSQuanHAdenomatous Polyp Prevention on Vioxx (APPROVe) Trial InvestigatorsCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med2005352109210215713943
   PubMed Web of Science ®Google Scholar
• BruneKHinzBSelective cyclooxygenase-2 inhibitors: similarities and differencesScand J Rheumatol2004331615124935
   PubMed Web of Science ®Google Scholar
• CannonCPCurtisSPFitzGeraldGAMEDAL Steering CommitteeCardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonLancet200636817718117113426
   PubMed Web of Science ®Google Scholar
• ChanATMansonJEAlbertCMNonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular eventsCirculation200611315788716534006
   PubMed Web of Science ®Google Scholar
• ChanFKPrimer: managing NSAID-induced ulcer complications - balancing gastrointestinal and cardiovascular risksNat Clin Pract Gastroenterol Hepatol200635637317008926
   PubMedGoogle Scholar
• EsserRBerryCDuZPreclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2Br J Pharmacol20051445385015655513
   PubMed Web of Science ®Google Scholar
• FarkouhMEGreenbergJDJegerRVCardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxibAnn Rheum Dis2007667647017412741
   PubMed Web of Science ®Google Scholar
• FarkouhMEKirshnerHHarringtonRATARGET Study GroupComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialLancet20043646758415325832
   PubMed Web of Science ®Google Scholar
• FitzgeraldGACOX-2 and beyondNature Rev Drug Discov2003879
   Google Scholar
• GeusensPAltenRRovenskyJEfficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritisInt J Clin Pract20045810334115605667
   PubMed Web of Science ®Google Scholar
• GoldkindLMedical officer’s gastroenterology advisory committee briefing document. Division of anti-inflammatory, analgesic and ophthalmologic drug products: HFP-5502000612 [online] Accessed 22 March 2006. URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.doc
   Google Scholar
• HarrisRCCOX-2 and the kidneyJ Cardiovasc Pharmacol200647Suppl 1S374216785827
   PubMed Web of Science ®Google Scholar
• HawkeyCJSvobodaPFiedorowicz-FabrycyIFGastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritisJ Rheum20043118041015338504
   PubMed Web of Science ®Google Scholar
• Hernandez-DiazDiazRodriguezLAAssociation between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990sArch Intern Med20001602093910904451
   PubMed Web of Science ®Google Scholar
• HochbergMCNew directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritisSemin Arthritis Rheum200232Suppl 141412528069
   PubMed Web of Science ®Google Scholar
• JamesMWHawkeyCJAssessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tractBr J Clin Pharmacol2003561465512895187
   PubMed Web of Science ®Google Scholar
• JordanKMArdenNKDohertyMStanding Committee for International Clinical Studies Including Therapeutic Trials ESCISITEULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)Ann Rheum Dis20036211455514644851
   PubMed Web of Science ®Google Scholar
• KearneyPMBaigentCGodwinJDo selective cyclooxygenase inhibitors and traditional non steroidal drugs increase the risk of athero-thrombosis? Meta-analysis of randomised trialsBMJ20063321302516740558
   PubMed Web of Science ®Google Scholar
• KerrDJDunnJALangmanMJVICTOR Trial GroupRofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancerN Engl J Med2007357360917652651
   PubMed Web of Science ®Google Scholar
• KivitzAJNayiagerSSchimanskyTReduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritisAliment Pharmacol Ther20041911899815153172
   PubMed Web of Science ®Google Scholar
• LaineLCurtisSPCryerBMEDAL Steering CommitteeAssessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparisonLancet20073694657317292766
   PubMed Web of Science ®Google Scholar
• LaineLHarperSSimonTA randomized trial comparing the effect of rofecoxib, a cyclo-oxygenase 2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology19991177768310500058
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKACurranMPLumiracoxibDrugs20046422374615456339
   PubMed Web of Science ®Google Scholar
• MangoldJBGuHRodriguezLCPharmacokinetics and metabolism of lumiracoxib in healthy male subjectsDrug Metab Dispos2004325667115100180
   PubMed Web of Science ®Google Scholar
• McGettiganPHenryDCardiovascular risk and inhibition of cyclo-oxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2JAMA200629616334416968831
   PubMed Web of Science ®Google Scholar
• NussmeierNAWheltonAABrownMTComplications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgeryNew Engl J Med200535210819115713945
   PubMed Web of Science ®Google Scholar
• OfmanJJMacLeanCHStrausWLMeta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugsJ Rheumatol2002298041211950025
   PubMed Web of Science ®Google Scholar
• RordorfCKellettNMairSGastroduodenal tolerability of lumiracoxib versus placebo and naproxen: a pilot endoscopic study in healthy male subjectsAliment Pharmacol Ther2003a185334112950426
   PubMed Web of Science ®Google Scholar
• RordorfCKellettNMairSGastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjectsAliment Pharmacol Ther2003b185334112950426
   PubMed Web of Science ®Google Scholar
• SchnitzerTJBurmesterGRMyslerETARGET Study GroupComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialLancet20043646657415325831
   PubMed Web of Science ®Google Scholar
• SchnitzerTJUpdate on guidelines for the treatment of chronic musculoskeletal painClin Rheumatol200625Suppl 1S22916741783
   PubMed Web of Science ®Google Scholar
• SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety StudyJAMA200028412475510979111
   PubMed Web of Science ®Google Scholar
• SinghGRecent considerations in nonsteroidal anti-inflammatory drug gastropathyAm J Med198810531S8S9715832
   PubMedGoogle Scholar
• SolomonDHSelective cyclo-oxygenase 2 inhibitors and cardiovascular eventsArthritis Rheum20055219687815986365
   PubMed Web of Science ®Google Scholar
• SolomonSDMcMurrayJJPfefferMAfor the Adenoma Prevention with Celecoxib (APC) Study InvestigatorsCardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionN Engl J Med200535210718015713944
   PubMed Web of Science ®Google Scholar
• VaneJRMitchellJAAppletonIInducible isoforms of cyclo-oxygenase and nitric-oxide synthase in inflammationProc Natl Acad Sci USA1994912046507510883
   PubMed Web of Science ®Google Scholar
• VonkemanHEBrouwersJRBJvan de LaarMAFJUnderstanding the NSAID related risk of vascular eventsBMJ2006332895816613964
   PubMed Web of Science ®Google Scholar
• WarnerTDGiulianoFVojnovicINonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysisProc Natl Acad Sci USA1999967563810377455
   PubMed Web of Science ®Google Scholar
• WolfeMMLichtensteinDRSinghGGastrointestinal toxicity of nonsteroidal antiinflammatory drugsN Engl J Med199934018889910369853
   PubMed Web of Science ®Google Scholar
• ZhangJDingELSongYAdverse effects of cyclooxygenase 2 inhibitors on renal and arrhytmia eventsJAMA200629616193216968832
   PubMed Web of Science ®Google Scholar